Evidence map›Paper›PMID 40119935›Full record

ReviewJournal of bone and mineral metabolism2025

Sequential therapy following teriparatide treatment in patients at high risk of osteoporotic patients.

Satoshi Mori

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of bone and mineral metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Satoshi MoriDepartment of Bone and Joint Surgery, Osteoporosis Center, Seirei Hamamatsu General Hospital, Hamamatsu, Japan. stmori@sis.seirei.or.jp.ORCID http://orcid.org/0000-0002-7660-5562

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of medications in sequence is recommended in several osteoporosis guidelines to afford the best protection for the patient at very high risk of fracture. Sequential therapy following once-weekly as well as daily teriparatide treatment is a potent option for those patients.

Indexed as

Bone Density Conservation AgentsOsteoporosisTeriparatideFemaleHumansRisk FactorsBone Density Conservation AgentsTeriparatideSequential therapysevere osteoporosisteriparatide

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.